Using companion and coupled diagnostics within strategy to personalize targeted medicines

Personalized Medicine
Donald R J Singer, John Watkins

Abstract

Regulatory authorities expect the pharmaceutical and biotechnology industries to accelerate their development of companion diagnostics and companion therapeutics towards the goal of personalized medicine, and expect health services to fund, prescribers to adopt and patients to accept these new therapeutic technologies. Expected benefits from more systematic development of combination products (companion diagnostic and its companion therapeutic) are expected to include safer and improved clinical and cost-effective use of medicines, more efficient patient selection for clinical trials, more cost-effective treatment pathways for health services, and a more profitable approach for drug developers. This review discusses challenges to timely development of companion diagnostics and provides case studies of single and multiple protein and genetic biomarkers of clinical response and risk of adverse drug effects.

References

Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P A Connelly, D F Stern
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P C Roche, J N Ingle
Sep 21, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kathleen UhlSandra L Kweder
Mar 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Annalise M MartinSimon Mallal
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Dec 23, 2006·Pharmacogenomics·Federico Innocenti, Mark J Ratain
Mar 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael G AmadoDavid D Chang
Mar 6, 2008·Neoplasia : an International Journal for Oncology Research·Sven PernerMark A Rubin
May 10, 2008·Journal of Chemotherapy·P BiasonG Toffoli
Aug 1, 2008·Current Clinical Pharmacology·Shufeng Zhou
Oct 2, 2008·Blood·Alfonso Quintás-Cardama, Jorge Cortes
Oct 4, 2008·The New England Journal of Medicine·Roy M GulickUNKNOWN MOTIVATE Study Teams
Feb 11, 2009·Nature Biotechnology·George S Mack
Mar 21, 2009·Nature Reviews. Drug Discovery·Jerel C DavisPhilip Ma
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Nov 17, 2009·Indian Journal of Dermatology, Venereology and Leprology·Timir Y MehtaRamesh K Goyal
Dec 15, 2010·Nature Reviews. Drug Discovery·Joseph A DiMasi, Laura B Faden
Feb 11, 2011·Human Mutation·Sarah C SimMagnus Ingelman-Sundberg
Apr 16, 2011·Pharmacology·Wojciech Leppert
May 7, 2011·Theranostics·Ekaterina Y Lukianova-HlebDmitri O Lapotko
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Dec 2, 2011·Nature Reviews. Drug Discovery·Alice T ShawPeter Kirkpatrick
Dec 14, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Alice T ShawMari Mino Kenudson
Mar 1, 2012·British Journal of Cancer·A J Atherly, D R Camidge
Mar 27, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Carsten BokemeyerClaus-Henning Köhne
Apr 21, 2012·Future Oncology·Guillem ArgilesJosep Tabernero
Apr 25, 2012·Nature Reviews. Clinical Oncology·Heikki Joensuu

❮ Previous
Next ❯

Citations

Dec 2, 2015·Genome Génome / Conseil National De Recherches Canada·Naazish S Bashir, Wendy J Ungar
Nov 19, 2013·Pharmacogenomics·James BuchananAnna Schuh

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
GTPase
pregnancy tests
contraception

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.